Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2019
Price :
$35
*
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections; Marburg virus disease
- Focus Adverse reactions
- Sponsors Crucell Holland
- 23 Feb 2019 12-month results published in the Journal of Infectious Diseases
- 07 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.